Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EWG pushes anew for final sunscreen monograph

This article was originally published in The Tan Sheet

Executive Summary

FDA before summer should issue enforceable sunscreen standards that include requirements for ultraviolet-A protection, the Environmental Working Group says. In an April 2 letter to FDA's Center for Drug Evaluation and Research Director Janet Woodcock, EWG encourages the agency to complete its health and safety reviews of new active ingredients awaiting approval so that sunscreen formulators in the U.S. can move forward with "safer" sunscreens. EWG cites the fact that while 29 ultraviolet filters have been approved in the European Union, only 17 are approved in the U.S. FDA has said it is aiming to release the final OTC sunscreen monograph in May (1"The Tan Sheet" March 1, 2010). An amended final version of the rule was released in 2007, but has been met with criticism from industry

You may also be interested in...



Environmental Group Opposes FDA Adding Triclosan To OTC Monographs

Environmental regulations could impede a group's attempt to block all non-medical uses of triclosan - including in OTC products

AstraZeneca's Risky Lynparza Endpoint In Pancreatic Cancer Goes Before Advisory Cmte.

US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Topics

UsernamePublicRestriction

Register

PS104013

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel